tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
crestor filmuhúðuð tafla 5 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg
asubtela (ethinylestradiol/drospirenon 0,03 mg/3 mg focus) filmuhúðuð tafla 3 mg/ 0,03 mg
exeltis healthcare s.l. - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/ 0,03 mg
crestor filmuhúðuð tafla 40 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg
crestor filmuhúðuð tafla 20 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg
crestor filmuhúðuð tafla 10 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg
ezetimib/simvastatin krka tafla 10 mg/ 40 mg
krka d.d. novo mesto* - simvastatinum inn; ezetimibe - tafla - 10 mg/ 40 mg
rosuvastatin actavis filmuhúðuð tafla 20 mg
actavis group ptc ehf. - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg
ibandronic acid wh filmuhúðuð tafla 50 mg
williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 50 mg
sitagliptin krka filmuhúðuð tafla 100 mg
krka d.d. novo mesto* - sitagliptinum inn - filmuhúðuð tafla - 100 mg